Wegovy (semaglutide 2.4 mg) is FDA-approved for chronic weight management, not type 2 diabetes. The same molecule, semaglutide, is sold at lower doses as Ozempic for type 2 diabetes. Using Wegovy specifically for diabetes is off-label, though the underlying drug lowers blood sugar through the same GLP-1 pathway. The distinction matters for insurance, dosing, and prescribing decisions.
Wegovy vs Ozempic: Same Drug, Different Labels
Both Wegovy and Ozempic are semaglutide, manufactured by Novo Nordisk. The FDA approved them separately because clinical trials were conducted for different indications and at different maximum doses. This is the single most misunderstood point in the conversation about GLP-1 drugs.
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| FDA indication | Chronic weight management | Type 2 diabetes |
| Maximum dose | 2.4 mg weekly | 2.0 mg weekly |
| Starting dose | 0.25 mg weekly | 0.25 mg weekly |
| CV risk reduction label | Yes (adults with CVD and overweight) | Yes (adults with T2D and CVD) |
| Pediatric approval | Age 12+ (obesity) | Adults only |
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist that mimics the gut hormone glucagon-like peptide-1. It:
- Boosts glucose-dependent insulin release from the pancreas
- Suppresses glucagon, which reduces liver glucose output
- Slows gastric emptying, producing earlier fullness
- Acts on brain appetite centers to reduce calorie intake
These mechanisms simultaneously lower blood sugar and body weight. That is why semaglutide improves A1C regardless of which brand name appears on the pen.
Why Wegovy Is Not Labeled for Diabetes
FDA approval is indication-specific. Wegovy’s trials (the STEP program) recruited adults with obesity or overweight with comorbidities, not adults with type 2 diabetes as the primary population. Ozempic’s trials (the SUSTAIN program) enrolled adults with type 2 diabetes. The data support each label. According to FDA prescribing information, clinicians and pharmacies must respect the approved indication for coverage and quality documentation, even when the molecule is identical.
Off-Label Use: What It Means
Off-label prescribing is legal and common in the United States. A clinician can prescribe Wegovy to a person with type 2 diabetes based on clinical judgment, especially when:
- Weight loss is the primary treatment goal
- The patient has not tolerated or responded to Ozempic’s dosing range
- Ozempic is unavailable due to shortage
- Insurance covers Wegovy but not Ozempic for that patient
Insurance, however, rarely covers off-label use. Most plans will not pay for Wegovy when the diagnosis code is type 2 diabetes, and they typically will not pay for Ozempic for obesity alone.
Clinical Evidence in Diabetes
While Wegovy itself is not labeled for diabetes, the STEP 2 trial evaluated semaglutide 2.4 mg in adults with type 2 diabetes and overweight or obesity. Results showed:
- Mean weight loss around 9.6 percent at 68 weeks
- A1C reduction of approximately 1.6 percent
- Greater improvements than semaglutide 1.0 mg (the Ozempic dose at the time)
According to the American Diabetes Association, semaglutide is considered a preferred GLP-1 agent for people with type 2 diabetes where weight loss and cardiovascular risk reduction are priorities.
Side Effects and Safety
The safety profile tracks the broader GLP-1 class:
- Nausea, vomiting, diarrhea, and constipation, especially during escalation
- Reflux, abdominal discomfort, and early satiety
- Gallbladder disease
- Pancreatitis (uncommon but requires discontinuation)
- Acute kidney injury from dehydration
- Severe hypoglycemia when combined with insulin or sulfonylureas
- Retinopathy complications (reported with semaglutide)
An FDA boxed warning notes potential thyroid C-cell tumor risk based on rodent data. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication.
Cost and Access Realities
Both brands are expensive without insurance. List prices are comparable, but coverage decisions by plan often drive real-world access more than clinical factors. People shopping for semaglutide should confirm the specific prior authorization criteria, formulary tier, and quantity limits with their plan before assuming either brand is affordable.
How It Fits in a Treatment Plan
Semaglutide, under whichever label, is one tool among many. It works best alongside dietary change, activity, and sleep. It does not replace foundational habits, and stopping the drug typically leads to regain of weight and rising glucose. For broader guidance on treatment options and lifestyle work, see our treatment hub and diet and nutrition guide. For context on how A1C changes translate into risk, review the A1C levels hub.
The Bottom Line
Wegovy is not FDA-approved for type 2 diabetes, though the semaglutide it contains lowers blood sugar as effectively as Ozempic. For diabetes specifically, Ozempic is the labeled option and usually the covered one. Discuss goals, insurance, and contraindications with your clinician rather than choosing between brands based on headlines. The molecule is the same; the labels, doses, and access rules are not.
This article is for educational purposes only and is not a substitute for personalized medical advice. Always consult a qualified healthcare provider about prescription medications.
